neuroendocrine tumor/distress vitamine
Conditions
Interventions
In the first four weeks after inclusion patients will get standard care.
Patients fill out the questionnaires at baseline, after four weeks, and after
18 weeks. The first month will be used to obser
diet
neuroendocrine tumor
tryptophane
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: • Adult NET patients (aged >= 18 years of age), with serotonine producing or non-serotonin producing tumors, with any tumor site and disease stage. • Use of somatostatin analogue for > 6 months. • Ability to comprehend Dutch (both reading and writing). • Written informed consent provided.
Exclusion criteria
Exclusion criteria: • Estimated life expectancy less than 3 months. • Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for >= 3 years. • • Major abdominal surgery during study period. • Known hypersensitivity of (components of) somatostatin analogue.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the difference in mean gastro-intestinal symptoms score of the EORTC QLQ-GINET21. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint will be distress measured by the distress thermometer and change in quality of life as determined by the cancer-specific EORTC QLQ-C30, and the other constructs of the EORTC QLQ-GINET21, empowerment (subscales of the Construct Empowering Outcomes (CEO) questionnaire) at end of study, the difference in nutrition state (Patient-Generated Subjective Global Assessment PG/SGA) and normalization of vitamins and tryptophan levels at end of study measured with quantitative analysis of blood and urine. | — |
Countries
The Netherlands
Outcome results
None listed